Reported about 8 hours ago
Oppenheimer has increased its price target for Acadia Pharmaceuticals (ACAD) from $17 to $19 while maintaining a Perform rating on the stock. The decision follows a Delaware court ruling that confirmed Acadia's patent protection for Nuplazid, alleviating concerns about potential legal issues and shifting investor focus back to the company's upcoming developments.
Source: YAHOO